92814-42-1

Basic information

• Product Name: (R)-6-amino-1,4-thiazepan-5-one
• Synonyms: (R)-6-amino-1,4-thiazepan-5-one;1,4-Thiazepin-5(2H)-one,6-aminotetrahydro-,(6R)-(9CI);(6R)-6-aMino-1,4-thiazepan-5-one;(R)-6-Amino-1,4-thiazepan-5-one hydrochloride
• CAS NO: 92814-42-1
• Molecular Formula: C₅H₁₀N₂OS
• Molecular Weight: 146.2107
• Product Categories: AMINEPRIMARY
• Mol File: 92814-42-1.mol

Chemical Properties

• Boiling Point: 389.7 °C at 760 mmHg
• Flash Point: 189.5 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: (R)-6-amino-1,4-thiazepan-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-6-amino-1,4-thiazepan-5-one(92814-42-1)
• EPA Substance Registry System: (R)-6-amino-1,4-thiazepan-5-one(92814-42-1)

Safety Data

• Hazardous Substances Data: 92814-42-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-6-amino-1,4-thiazepan-5-one is used as a key intermediate in the synthesis of novel drugs for neurological and psychiatric disorders. Its unique structure and properties make it a valuable candidate for the development of new therapeutic agents that can address unmet medical needs in these areas.
Used in Mood Disorder Treatment:
(R)-6-amino-1,4-thiazepan-5-one is used as a potential therapeutic agent for treating mood disorders. Its research is focused on understanding its effects on neurotransmitter systems and how it can modulate mood-related pathways to provide relief for patients suffering from mood disorders.
Used in Anxiety Treatment:
(R)-6-amino-1,4-thiazepan-5-one is used as a potential anxiolytic agent. Studies are being conducted to explore its ability to alleviate anxiety symptoms by interacting with specific receptors or pathways in the brain, offering a new approach to anxiety management.
Used in Anti-inflammatory and Immunomodulatory Therapies:
(R)-6-amino-1,4-thiazepan-5-one is used as a compound with anti-inflammatory and immunomodulatory properties. Its potential to modulate the immune system and reduce inflammation makes it a candidate for the development of new therapies for various medical conditions where inflammation plays a significant role.

InChI:InChI=1/C5H10N2OS/c6-4-3-9-2-1-7-5(4)8/h4H,1-3,6H2,(H,7,8)

Upstream product

• 2485-62-3 L-Cysteine methyl ester 
• 870-24-6 2-chloroethanamine hydrochloride 
• 18598-63-5 L-cysteine methyl ester hydrochloride 

Downstream Products

• 256656-63-0 {(S)-2-[4-(Bis-benzyloxy-phosphoryloxy)-phenyl]-1-[(R)-4-(3-cyclohexyl-propyl)-5-oxo-[1,4]thiazepan-6-ylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 911304-55-7 N-{(R)-4-[((S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-1,1,5-trioxo-1λ⁶-[1,4]thiazepan-6-yl}-3-trifluoromethyl-benzamide 
• 911304-49-9 N-{(R)-4-[((S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-5-oxo-[1,4]thiazepan-6-yl}-3-trifluoromethyl-benzamide 
• 635706-30-8 N-{(R)-4-[((S)-2-ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyI]-1,1,5-trioxo-1λ6-[1,4]thiazepan-6-yl}-benzamide 
• 635706-28-4 N-{(R)-4-[((S)-2-ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-methyl]-5-oxo-1-[1,4]thiazepan-6-yl}-benzamide 
• 911304-61-5 [(R)-5-Oxo-6-(3-trifluoromethyl-benzoylamino)-[1,4]thiazepan-4-yl]-acetic acid ethyl ester 
• 911304-65-9 [(R)-5-Oxo-6-(3-trifluoromethyl-benzoylamino)-[1,4]thiazepan-4-yl]-acetic acid 
• 635706-26-2 ((R)-6-benzoylamino-5-oxo-[1,4]thiazepa-4-yl)-acetic acid ethyl ester 
• 635706-27-3 ((R)-6-benzoylamino-5-oxo-[1,4]thiazepa-4-yl)-acetic acid 
• 256656-62-9 [(S)-2-[4-(Bis-benzyloxy-phosphoryloxy)-phenyl]-1-((R)-5-oxo-[1,4]thiazepan-6-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis and evaluation of thiazepines as interleukin-1β converting enzyme (ICE) inhibitors

A series of monocyclic thiazepine inhibitors of interleukin-1β converting enzyme (ICE) were synthesized in eight steps from commercially available intermediates. In vitro biological evaluation showed the thiazepines to be moderately potent ICE inhibitors,

SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS

The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated

DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS

The present invention relates to interleukin - Iβ converting enzyme inhibitors of formula I: wherein each X is independently selected from: i) -C(W)2-; ii) -C(O)-; iii) -NR2-; iv) -S-; v) -S(O)-; vi) -S(O)2-; vii) two units, one from each adjacent X unit,